US · CERT
Certara, Inc.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Princeton, NJ 08540
- Website
- certara.com
Price · as of 2025-12-31
$6.18
Market cap 1.13B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.16 | +371.84% |
| Intrinsic Value(DCF) | $3.49 | -43.53% |
| Graham-Dodd Method(GD) | $1.76 | -71.6% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $27.44 | $36.63 | $0.41 | $0.37 | $0.00 |
| 2021 | $18.96 | $34.10 | $1.64 | $1.82 | $0.00 |
| 2022 | $19.52 | $36.82 | $1.15 | $2.78 | $2.33 |
| 2023 | $19.36 | $34.56 | $0.48 | $0.34 | $0.00 |
| 2024 | $11.73 | $30.74 | $0.78 | $1.50 | $0.00 |
| 2025 | $7.05 | $29.16 | $0.98 | $1.75 | $0.00 |
AI valuation
Our deep-learning model estimates Certara, Inc.'s (CERT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.16
- Current price
- $6.18
- AI upside
- +371.84%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.49
-43.53% upside
Graham-Dodd
$1.76
-71.6% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CERT | Certara, Inc. | $6.18 | 1.13B | +372% | -44% | -72% | — | -708.95 | 1.06 | 2.70 | 11.35 | — | -7.16 | 61.53% | 5.02% | -0.38% | -0.15% | 0.81% | -0.10% | 0.01 | 1.06 | 2.05 | 1.91 | -2.12 | -8668.00% | 875.00% | 1994.00% | 8.36% | 0.63 | 9.11% | 0.00% | 0.00% | 31.25% | 45.34 | 10.08 | 2.27 | 1.70 |
| AVAH | Aveanna Healthcare Holdin… | $7.36 | 1.54B | — | +111% | — | — | -67.95 | -6.08 | 0.37 | 11.53 | — | -0.59 | 31.39% | 6.90% | -0.54% | — | — | — | -12.30 | 0.89 | 0.98 | 0.90 | 7.57 | — | — | — | 3.54% | 0.08 | — | 0.00% | 0.00% | 0.00% | 15.45 | 82.09 | 1.07 | 0.57 |
| CLOV | Clover Health Investments… | $2.09 | 1.08B | +1,430% | +6,971% | — | — | -12.33 | 3.42 | 0.55 | -11.45 | -13.17 | 3.45 | 103.58% | -4.44% | -4.45% | -26.33% | -51.38% | -15.25% | 0.00 | — | 1.47 | 0.46 | 0.93 | 9362.00% | 4034.00% | -30721.00% | -6.54% | -0.32 | -41.43% | 0.00% | 0.00% | 0.10% | -11.22 | -13.92 | 0.50 | 0.06 |
| OMCL | Omnicell, Inc. | $41.10 | 1.89B | +33% | -57% | -73% | -98% | 924.00 | 1.54 | 1.60 | 19.91 | — | 5.86 | 42.49% | 0.44% | 0.17% | 0.17% | 0.17% | 0.10% | 0.18 | 0.84 | 1.43 | 0.87 | 0.21 | -8359.00% | 653.00% | -4256.00% | 4.58% | 0.27 | 6.96% | 0.00% | 0.00% | 4.09% | 371.46 | 22.06 | 1.62 | 2.26 |
| PGNY | Progyny, Inc. | $17.69 | 1.53B | +175% | +6% | -48% | -30% | 25.63 | 2.91 | 1.16 | 12.09 | 182.64 | 3.06 | 23.63% | 6.62% | 4.54% | 12.48% | 23.59% | 8.67% | 0.05 | — | 2.73 | 2.62 | -0.88 | 1404.00% | 1040.00% | 1041.00% | 12.78% | 1.04 | 86.52% | 0.00% | 0.00% | 5.44% | 14.24 | 6.33 | 0.94 | 6.66 |
| QDEL | QuidelOrtho Corporation | $22.74 | 1.54B | -6% | -60% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| SDGR | Schrödinger, Inc. | $12.06 | 888.4M | +184% | -53% | — | — | -8.64 | 2.45 | 3.49 | -6.29 | — | 2.48 | 55.74% | -65.23% | -40.36% | -26.29% | -125.97% | -13.33% | 0.30 | — | 2.75 | 2.53 | 1.26 | -4514.00% | 2329.00% | -10756.00% | 1.40% | 0.07 | 9.40% | 0.00% | 0.00% | 10.29% | -3.63 | 48.66 | 2.37 | 0.41 |
| TWST | Twist Bioscience Corporat… | $46.92 | 2.88B | -25% | -66% | -100% | — | -24.87 | 4.08 | 5.13 | -35.25 | — | 5.12 | 50.72% | -36.18% | -20.63% | -16.43% | -41.34% | -12.37% | 0.29 | — | 3.64 | 3.17 | 0.88 | -6389.00% | 2032.00% | 934.00% | -3.92% | -0.52 | -22.95% | 0.00% | 0.00% | 0.00% | -13.48 | -24.28 | 4.88 | 4.32 |
| TXG | 10x Genomics, Inc. | $23.05 | 2.94B | +141% | -55% | -80% | — | -66.29 | 3.63 | 4.49 | -22.74 | — | 3.96 | 69.05% | -17.25% | -6.77% | -5.78% | -26.72% | -4.44% | 0.20 | — | 4.46 | 3.95 | 2.85 | -7697.00% | 525.00% | -237116.00% | 4.51% | 0.89 | 31.35% | 0.00% | 0.00% | 1.90% | -22.74 | 19.38 | 3.92 | 5.92 |
| VCEL | Vericel Corporation | $35.68 | 1.8B | +34% | -39% | -76% | -78% | 108.30 | 5.04 | 6.48 | 57.69 | 180.50 | 5.13 | 74.42% | 4.00% | 5.98% | 5.11% | 3.57% | 3.59% | 0.27 | 7.10 | 5.03 | 4.52 | -0.13 | 6000.00% | 1645.00% | -52588.00% | 1.38% | 1.06 | 8.42% | 0.00% | 0.00% | 1.57% | 158.24 | 70.62 | 6.33 | 8.10 |
About Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
- CEO
- Jon Resnick
- Employees
- 1.49K
- Beta
- 1.48
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.49 ÷ $6.18) − 1 = -43.53% (DCF, example).